UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
University of California, Davis
University of California, Davis
M.D. Anderson Cancer Center
Abramson Cancer Center at Penn Medicine
Thomas Jefferson University
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Masonic Cancer Center, University of Minnesota
Northwestern University